CELLULAR/MOLECULAR ANALYSES SHARED RESOURCE: BIOLOGICAL IMAGING FACILITY (BIF) PROJECT SUMMARY/ABSTRACT The Biological Imaging Facility (BIF) provides Cancer Center members the capabilities to obtain the highest quality images to facilitate their research. The BIF under the direction of Timothy Yen, PhD (CB), and a staff of 2.4 FTEs, provide services at the ultrastructural (Electron Microscope (EM)), subcellular and cellular (Light Microscope (LM)) levels, and tissues and organs in small animals (Small Animal Imaging (SAI)). The BIF accommodates diverse experimental models that include mice, zebrafish, Drosophila, and mammalian cells in culture. The BIF staff provides training to use equipment so that users become proficient at collecting and analyzing their own data. Many of the advanced technologies enable real-time studies in live cells and animals. The SAI Manager trains users to operate our high-field MRI system (7-Tesla Bruker DRX) for anatomic imaging, a Caliperls IVIS spectrum that detects luciferase or fluorescently tagged cells in animals, and a Visen FMT2500 which detects the three dimensional distribution of enzymatically activated optical probes (metalloproteinases, cathepsin, elastase) or fluorescently tagged probes in live animals. The BIF offers fee-for- service in cases where investigators cannot devote lab personnel or, for projects requiring EM and SKY (spectral karyotyping) where they rely on the expertise of dedicated staff. The BIF staff is familiar with ongoing projects as they contribute to experimental design and data analysis, the latter of which may require advanced computational methods (i.e. deconvolution, 3D rendering, quantitation, 3D spatial registration of anatomical images obtained from the same animal but using different platforms). Imaging technology plays an essential role in modern cancer research, and is used in a diverse array of laboratories as evidenced by the 30 Cancer Center members who used the BIF in calendar year 2014. 88% of service hours logged for instrument use in 2014 were in support of peer-review funded research. 56 Cancer Center members from all 5 Research Programs used the BIF in the period 2011-2014. The experience of the Facility Director, Yen, is key in implementing state-of-the-art technology and new approaches. Yen's leadership coupled with institutional commitment of $449,600 led to the purchase of two newly acquired Leica SP8 confocal systems. A major value added of the BIF is that it is the most cost effective way to provide users with advanced imaging technologies that are too costly to purchase and support by any individual lab. These services cannot be outsourced. The staff provides stability by ensuring users access to properly functioning instruments. This is critical for time sensitive experiments that involve animals. The BIF is advised by a dedicated Facility Advisory Committee (FAC) that meets annually. Recommendations from the FAC are directed to a governing Facility Parent Oversight Committee that serves to ensure that the BIF continues to have the necessary resources to provide the highest quality imaging services for Cancer Center members. Demand for services is expected to increase in the next cycle of the CCSG due to plans to recruit in all 5 Programs and increased TU usage.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-54
Application #
9754596
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
54
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Fahl, Shawn P; Coffey, Francis; Kain, Lisa et al. (2018) Role of a selecting ligand in shaping the murine ??-TCR repertoire. Proc Natl Acad Sci U S A 115:1889-1894
Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961

Showing the most recent 10 out of 1280 publications